RXRG and breast carcinoma: There is evidence that rexinoids are more effective anti-cancer agents than retinoids in preclinical models and show minimal toxicity.62 Therefore, further studies to validate the potential of RXRG as a therapeutic target in breast cancer are therefore warranted.